Levitt Comments on Dilemmas Text Messages Pose for E-Discovery
July 21, 2017
Corporate Counsel
In Corporate Counsel’s article, “Texts Generate New E-Discovery Dilemmas for In-House Counsel,” Partner Melinda Levitt commented on the implications for in-house counsel of preserving text messages for e-discovery policies and litigation holds, as more text messaging becomes more predominant in the business setting.
The challenges faced by in-house counsel because of the increased reliance on text messages are not unlike those that attorneys grappled with years ago in figuring out how to properly preserve emails, Levitt said. “It’s a challenge, but we said the same thing about emailing and other things that have come along through the years. And, the legal world has at least come up with workable solutions, if not perfect ones.”
The challenges faced by in-house counsel because of the increased reliance on text messages are not unlike those that attorneys grappled with years ago in figuring out how to properly preserve emails, Levitt said. “It’s a challenge, but we said the same thing about emailing and other things that have come along through the years. And, the legal world has at least come up with workable solutions, if not perfect ones.”
People
Related News
July 21, 2025
In the News
Nicholas O'Keefe Assesses 'Golden Share' in US Steel Deal
Foley & Lardner LLP partner Nicholas O'Keefe commented on the 'golden share' arrangement included as part of the approval of Nippon Steel's acquisition of U.S. Steel in Agenda, a Financial Times publication.
July 18, 2025
In the News
Matt Caplan Featured for Arrival to Foley – 'It's an exciting time'
Foley & Lardner LLP partner Matt Caplan is highlighted across press for his recent arrival to the firm's San Francisco office.
July 18, 2025
In the News
David Rosen on FDA's CRL Release – 'It hasn't happened in the past'
Foley & Lardner LLP partner David Rosen commented on the U.S. Food and Drug Administration's decision to publish a package of complete response letters to pharmaceutical companies in the PharmaVoice article, "Why FDA’s CRL release could open the door to lawsuits against pharma."